Dimitrios Bourikas
Research Subjects
Research Interests
Dimitrios Bourikas has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Brian Darryl Moseley
UCB, 4000 Paramount Pkwy, Morrisville, NC, 27560, USA.
4 shared publications - Florin Floricel
UCB Pharm, Alfred Nobel Str 10, D-40789 Monheim, Germany
3 shared publications - Pavel Klein
Mid-Atlantic Epilepsy and Sleep Center, Bethesda, USA
3 shared publications - Sami Elmoufti
UCB Pharma, Morrisville, NC, USA
3 shared publications - Svetlana Dimova
UCB Pharma, Brussels, Belgium
3 shared publications - Christine de la Loge
UCB, Allée de la Recherche 60, Brussels 1070, Belgium
2 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 174, 110799
Experiences of women of childbearing age with epilepsy throughout their motherhood journey: Results from a social media listening study
- 21 November 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 174, 110799
Open AccessExperiences of women of childbearing age with epilepsy throughout their motherhood journey: Results from a social media listening study
- Open Access
- 29 July 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110569
Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial
- 29 July 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110569
Open AccessLong-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial
- Open Access
- 21 November 2024
- Published by Elsevier in Epilepsy Research
- Vol. 209, 107482
Long-term efficacy and tolerability of brivaracetam in pediatric patients with focal-onset seizures and cognitive or learning comorbidities: Post hoc analysis of an open-label trial
- 21 November 2024
- Published by Elsevier in Epilepsy Research
- Vol. 209, 107482
Open AccessLong-term efficacy and tolerability of brivaracetam in pediatric patients with focal-onset seizures and cognitive or learning comorbidities: Post hoc analysis of an open-label trial
- Open Access
- 30 August 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 159, 109989
Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy
- 30 August 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 159, 109989
Open AccessLong-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy
- Open Access
- 5 July 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 158, 109922
Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies
- 5 July 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 158, 109922
Open AccessBrivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies
- Open Access
- 29 May 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (7) , 2682-2699
Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy
One third of patients with epilepsy will continue to have uncontrolled seizures despite treatment with antiseizure medications (ASMs). There is therefore a need to develop novel ASMs. Brivaracetam (BRV) is an ASM that was developed in a major drug discovery program aimed at identifying selective, high-affinity synaptic vesicle protein 2A (SV2A) ligands, the target molecule of levetiracetam. BRV binds to SV2A with 15- to 30-fold higher affinity and greater selectivity than levetiracetam. BRV has broad-spectrum antiseizure activity in animal models of epilepsy, a favorable pharmacokinetic profile, few clinically relevant drug-drug interactions, and rapid brain penetration. BRV is available in oral and intravenous formulations and can be initiated at target dose without titration. Efficacy and safety of adjunctive BRV (50–200 mg/day) treatment of focal-onset seizures was demonstrated in three pivotal phase III trials (NCT00490035/NCT00464269/NCT01261325), including in patients who had previously failed levetiracetam. Efficacy and safety of adjunctive BRV were also demonstrated in adult Asian patients with focal-onset seizures (NCT03083665). In several open-label trials (NCT00150800/NCT00175916/NCT01339559), long-term safety and tolerability of adjunctive BRV was established, with efficacy maintained for up to 14 years, with high retention rates. Evidence from daily clinical practice highlights BRV effectiveness and tolerability in specific epilepsy patient populations with high unmet needs: the elderly (≥ 65 years of age), children (< 16 years of age), patients with cognitive impairment, patients with psychiatric comorbid conditions, and patients with acquired epilepsy of specific etiologies (post-stroke epilepsy/brain tumor related epilepsy/traumatic brain injury-related epilepsy). Here, we review the preclinical profile and clinical benefits of BRV from pivotal trials and recently published evidence from daily clinical practice.
- 29 May 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (7) , 2682-2699
Open AccessNarrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy
One third of patients with epilepsy will continue to have uncontrolled seizures despite treatment with antiseizure medications (ASMs). There is therefore a need to develop novel ASMs. Brivaracetam (BRV) is an ASM that was developed in a major drug discovery program aimed at identifying selective, high-affinity synaptic vesicle protein 2A (SV2A) ligands, the target molecule of levetiracetam. BRV binds to SV2A with 15- to 30-fold higher affinity and greater selectivity than levetiracetam. BRV has broad-spectrum antiseizure activity in animal models of epilepsy, a favorable pharmacokinetic profile, few clinically relevant drug-drug interactions, and rapid brain penetration. BRV is available in oral and intravenous formulations and can be initiated at target dose without titration. Efficacy and safety of adjunctive BRV (50–200 mg/day) treatment of focal-onset seizures was demonstrated in three pivotal phase III trials (NCT00490035/NCT00464269/NCT01261325), including in patients who had previously failed levetiracetam. Efficacy and safety of adjunctive BRV were also demonstrated in adult Asian patients with focal-onset seizures (NCT03083665). In several open-label trials (NCT00150800/NCT00175916/NCT01339559), long-term safety and tolerability of adjunctive BRV was established, with efficacy maintained for up to 14 years, with high retention rates. Evidence from daily clinical practice highlights BRV effectiveness and tolerability in specific epilepsy patient populations with high unmet needs: the elderly (≥ 65 years of age), children (< 16 years of age), patients with cognitive impairment, patients with psychiatric comorbid conditions, and patients with acquired epilepsy of specific etiologies (post-stroke epilepsy/brain tumor related epilepsy/traumatic brain injury-related epilepsy). Here, we review the preclinical profile and clinical benefits of BRV from pivotal trials and recently published evidence from daily clinical practice.
- Open Access
- 23 May 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 156, 109844
Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures
- 23 May 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 156, 109844
Open AccessTime-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures